Related Experiment Video
Updated: Aug 12, 2026
12:59
Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
Rosiglitazone improves exercise capacity in individuals with type 2 diabetes
Judith G Regensteiner1, Timothy A Bauer, Jane E B Reusch
1Division of Internal Medicine, Center for Women's Health Research, Box B-180, University of Colorado Health Sciences Center, 4200 E. 9th Ave., Denver, CO 80262, USA. judy.regensteiner@uchsc.edu
Diabetes Care
|November 25, 2005
Summary
Thiazolidinedione (TZD) treatment improved exercise capacity in type 2 diabetes patients by enhancing insulin sensitivity and endothelial function. This study highlights a potential new therapeutic avenue for improving physical function in this population.
Area of Science:
- Endocrinology
- Exercise Physiology
- Cardiovascular Medicine
Background:
- Type 2 diabetes is often associated with impaired exercise capacity, linked to insulin resistance and endothelial dysfunction.
- Exercise is crucial for type 2 diabetes management but patient adoption is often low.
- Understanding factors limiting exercise capacity is key to improving patient outcomes.
Purpose of the Study:
- To investigate the effect of a thiazolidinedione (TZD) agent on exercise capacity in individuals with type 2 diabetes.
- To determine if TZDs can improve maximal oxygen consumption (VO2max), insulin sensitivity, and endothelial function.
- To explore the correlation between improvements in exercise capacity and metabolic/vascular markers.
Main Methods:
- A double-blind, placebo-controlled study involving 20 participants with uncomplicated type 2 diabetes.
- Participants received either rosiglitazone (a TZD) or a placebo for 4 months.
- Key assessments included endothelial function (brachial artery diameter), VO2max, oxygen uptake kinetics, and insulin sensitivity via hyperinsulinemic-euglycemic clamp.
Main Results:
- Rosiglitazone treatment significantly improved VO2max, insulin sensitivity, and endothelial function compared to placebo.
- Improvements in VO2max correlated strongly with enhanced insulin sensitivity (r=0.68) and brachial artery diameter (r=0.70).
- No significant changes in VO2max or endothelial function were observed in the placebo group.
Conclusions:
- This study provides the first evidence that a TZD agent can enhance exercise function in type 2 diabetes.
- Observed improvements may be attributed to enhanced insulin sensitivity and/or endothelial function.
- Further research is needed to elucidate the precise mechanisms underlying TZD-mediated improvements in exercise capacity.
Related Concept Videos
01:22Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...